Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jjwilsonon Feb 21, 2018 3:56pm
158 Views
Post# 27597011

RE:Understanding share consolidations.

RE:Understanding share consolidations."It's abundantly clear you have no concept of how destructive consolidations or stock rollbacks are, and how they affect all shareholders but especially so, those that have supported any company from an early stage development perspective. "

Yes, it's true, consolidations can be a bad deal for shareholders but I think you're making an error here.

If some company comes along and is willing to pay for something we have the share price and whether or not there has been a consolidation is irrelevant.  The price that some company might be willing to pay is completely independent of the share price.

Look, if you're in this for a short time and are just waiting for the price to hit a buck/share so you can cash out then, yes, a consolidation might be bad but if you have your shares and are waiting for a buyout/partnership deal then the share price is meaningless.  When the deal comes it will be an up-front payment and then milestone payments or a lump sum for outright ownership of a part of the company or a lump sum for the whole company - none of those are affected by the share price - doesn't matter if the price is 50 cents/share, a dollar/share or 10 cents/share the day before.

A billion dollars divided by 250 million shares is 4.00/share.  After a 10-1 consolidation you'd have 1/10 the shares in your account but you'd get 10 times the payout - $40.00/share.  It's the payout divided by the share count that matters, not share price.

Share price matters when you're buying because you get more or less shares for your available investment.  Share price matters when a PP is done because it affects the dilution.  Share price matters for getting listed and/or staying listed on a particular board.  Share price does not matter for a company like PMN and the sort of buyout/deal that has be discussed on this board.

I like to look at my holdings page and see a bigger number than I saw yesterday but the number I see there, bigger or smaller, has no correlation to the ultimate value I expect to see.
Bullboard Posts